WHAT IS CLAIMED IS:

1. A compound of formula (I), or its pharmaceutical acceptable salt,



(I)

wherein, R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22} and R^{23} independently from each other are H or D, and at least one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty one, twenty two or twenty three of R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22} and R^{23} is D.

2. The compound or its pharmaceutical acceptable salt of claim 1, wherein at least one, two, three or four of R^6, R^7, R^8 and R^9 is D. optionally no more than one, two, three or four of R^6, R^7, R^8 and R^9 is D, optionally all of R^1, R^2, R^3, R^4, R^5, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22} and R^{23} are H.

3. The compound or its pharmaceutical acceptable salt of claim 1, wherein one or two of R^6 or R^7 is D, optionally all of R^1, R^2, R^3, R^4, R^5, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22} and R^{23} are H.

4. The compound or its pharmaceutical acceptable salt of claim 1, wherein one or two of R^8 or R^9 is D, optionally all of R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22} and R^{23} are H.

5. The compound or its pharmaceutical acceptable salt of claim 1, wherein all of R^1, R^2, R^3, R^4 and R^5 are D, and all of R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22} and R^{23} are H.

6. The compound or its pharmaceutical acceptable salt of claim 1, wherein at least one, two, three, four or five of R^1, R^2, R^3, R^4 and R^5 is D and at least one, two, three, or four of R^6, R^7, R^8 and R^9 is D, preferably at least one, two, three, four or five of R^1, R^2, R^3, R^4 and R^5 is D and at least one or two of R^8 and R^9 is D, more preferably at least one or two of R^1 and R^5 is D and at least one or two of R^8 and R^9 is D.

7. The compound or its pharmaceutical acceptable salt of claim 1, wherein at least one, two or three of R^{12}, R^{13} and R^{14} is D, optionally no more than one, two or three of R^{12}, R^{13} and R^{14} is D, preferably at least one or two of R^{12} and R^{13} is D and R^{14} is D, and optionally all of R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{15}, R^{16}, R^{17}, R^{18}, R^{19}, R^{20}, R^{21}, R^{22} and R^{23} are H.

8. The compound or its pharmaceutical acceptable salt of claim 1, wherein at least one, two or three of R^{16}, R^{17} and R^{18} is D, optionally no more than one, two or three of R^{16}, R^{17} and R^{18} is D, optionally all of R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{19}, R^{20}, R^{21}, R^{22} and R^{23} are H.

9. The compound or its pharmaceutical acceptable salt of claim 1, wherein at least one, two, three, four, five, six, seven, eight, nine, ten, eleven or twelve of R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{16}, R^{17} and R^{18} is D, optionally no more than one, two, three, four, five, six, seven, eight, nine, ten, eleven or twelve of R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{16}, R^{17} and R^{18} is D, optionally all of, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}, R^{19}, R^{20}, R^{21}, R^{22} and R^{23} are H.

10. The compound or its pharmaceutical acceptable salt of claim 1, wherein at least one or two of R^8 and R^9 is D and at least one, two or three of R^{16}, R^{17} and R^{18} is D; or at least one, two, three, four or five of R^1, R^2, R^3, R^4, and R^5 is D and at least one, two or three of R^{16}, R^{17} and R^{18} is D.

11. A compound of formula (Ia), or its pharmaceutical acceptable salt,



(Ia)

wherein, $R^{6'}$, $R^{7'}$, $R^{8'}$ and $R^{9'}$ independently from each other are H or D, wherein at least one, two, three or four of $R^{6'}$, $R^{7'}$, $R^{8'}$ and $R^{9'}$ is D.

12. The compound or its pharmaceutical acceptable salt of claim 11, wherein both of $R^{6'}$ and $R^{7'}$ are H when at least one or two of $R^{8'}$ and $R^{9'}$ is D.

13. The compound or its pharmaceutical acceptable salt of claim 11, wherein both of $R^{8'}$ and $R^{9'}$ are H when at least one or two $R^{6'}$ and $R^{7'}$ of is D.

14. A compound selected from



1



2



3



4



5



6



7



8



9



10



11



12

, or its pharmaceutical acceptable salt.

15. The compound or its pharmaceutical acceptable salt of any one of claims 1-14, wherein deuterium enrichment is no less than 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99%, optionally no more than 99.9%, 99%, 98%, 97%, 96%, 95%, or 90%.

16. A pharmaceutical composition comprising a compound or its pharmaceutical acceptable salt of any one of claims 1-15 and a pharmaceutically acceptable carrier and/or adjuvant.

17. The use of a dual agonist of PPARα and PPARγ in the manufacture of a medicament for the treatment and/or prophylaxis of diseases which are modulated by PPARα and/or PPARγ agonists, wherein the dual agonist of PPARα and PPARγ is deuterated.

18. The use of claim 17, wherein the disease is diabetes, non-insulin dependent diabetes mellitus, elevated blood pressure, dyslipidemia, atherosclerotic diseases, metabolic syndrome, or diabetic nephropathy, or renal injury, preferably renal injury caused by ureteral obstruction or unilateral ureteral obstruction.

19. The use of claim 17, wherein the dual agonist of PPARα and PPARγ is deuterated Aleglitazar or its pharmaceutical acceptable salt, optionally the compound or its pharmaceutical acceptable salt of claim 1.

20. A method for modulating (e.g., improving) the specific agonistic activity of PPARα or PPARγ of a dual agonist of PPARα and PPARγ, comprising deuterating the dual agonist, optionally wherein the dual agonist of PPARα and PPARγ is deuteratedAleglitazar or its pharmaceutical acceptable salt, optionally the compound or its pharmaceutical acceptable salt of claim 1.